Heart failure is a severe disease affecting approximately 1-2% of the adult population in developed countries and around 26 million people worldwide. Up to 10% of these patients are in advanced stage heart failure, which is defined by a significant morbimortality and considerable medical expenses. Despite advances in its medical management, advanced (or end stage) heart failure is characterized by refractoriness to conventional therapies including guideline-directed pharmacological and non-surgical device treatments. These patients remain severely symptomatic (NYHA IV) and have objective signs of congestion or low cardiac output. Left ventricular assist devices (LVADs) have been used in patients with heart failure with reduced ejection fraction for almost 20 years either as an alternative or a bridge to heart transplantation. LVADs improve heart failure symptoms and survival at the cost of increased rates of infection, stroke and bleeding. Despite the lack of evidence, LVAD implantation in ambulatory patients is not rare, with INTERMACS profiles ≥4 patients representing 15.7% of the overall population implanted between 2012 and 2016. The aim of this study is to investigate the efficacy and safety of left ventricular assist devices compared to traditional HF medical treatment alone in a population of ambulatory advanced heart failure patients. Secondary objectives are to better identify subgroups of patients that would benefit the most from the implantation of an LVAD as well as to assess the optimal timing of intervention.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
All-cause mortality rate
Timeframe: Through 24 months when the last subject completes 12 months of follow-up
Number of urgent ECMO implantation
Timeframe: Through 24 months when the last subject completes 12 months of follow-up
Number of urgent heart transplantation
Timeframe: Through 24 months when the last subject completes 12 months of follow-up
Number of LVAD implantation
Timeframe: Through 24 months when the last subject completes 12 months of follow-up
Number of unplanned hospitalization for heart failure
Timeframe: Through 24 months when the last subject completes 12 months of follow-up
Quality of life assessed by KCCQ score
Timeframe: Through 24 months when the last subject completes 12 months of follow-up
Distance in meters at 6-min walking test
Timeframe: Through 24 months when the last subject completes 12 months of follow-up